Search

A clinical trial, NCT06745128, is being conducted to evaluate the feasibility and preliminary efficacy of using tirzepatide for individuals with comorbid obesity and methamphetamine use disorder. The study will enroll up to 30 participants with moderate-to-severe methamphetamine use disorder who meet the FDA-approved weight-related indication for tirzepatide. Participants will receive weekly treatment with tirzepatide for a 32-week period, followed by a 4-week observational follow-up, and will undergo clinical and laboratory assessments during weekly visits. The trial aims to assess the effect of tirzepatide on self-reported methamphetamine use, changes in body mass index, symptoms of anhedonia, high-sensitivity C-reactive protein levels, and gastrointestinal symptom severity. [Extracted from the article]

A study conducted in Zhejiang, People's Republic of China, evaluated the efficacy and safety of combining recombinant human brain natriuretic peptide (rhBNP) with sacubitril/valsartan in treating senile patients with acute heart failure. The research involved 136 patients over 60 years old and found that the sequential treatment group showed better outcomes in terms of symptom remission, hospitalization duration, and improvement in heart function compared to the standard treatment and rhBNP groups. The study concluded that the sequential treatment significantly improved clinical symptoms, enhanced cardiac function, and reduced myocardial damage in elderly patients with acute heart failure. [Extracted from the article]

A recent study from the University of Utah discusses a case of acquired lipodystrophy induced by pembrolizumab, a type of immunotherapy used to treat melanoma. The patient experienced significant weight loss, metabolic complications, and insulin dependence after treatment. The study highlights the rarity and clinical consequences of this condition, emphasizing the need for further research to understand its mechanisms and guide clinical management. [Extracted from the article]

The article discusses a study that suggests the colon may be an extra-pancreatic source of glucagon, a hormone typically associated with the pancreas. The research, conducted in a mouse model of pancreatectomy, indicates that the colon can produce and secrete glucagon, potentially impacting glucose control in diabetic patients who have undergone pancreatectomy. These findings could lead to new therapeutic strategies for managing glucose levels in diabetic individuals. The study has not yet undergone peer review. [Extracted from the article]

Researchers from NU Hospital Group have reported findings on the potential role of leukotrienes in the pathogenesis of type 1 diabetes, specifically in reducing insulin requirements in patients. A case study involving a 55-year-old male with Latent Autoimmune Diabetes in Adults (LADA) showed significant reductions in insulin dosage when treated with montelukast, a leukotriene receptor antagonist, for respiratory symptoms. The study suggests that montelukast may have anti-inflammatory effects on eosinophils, highlighting the need for further research into its role in managing type 1 diabetes and potentially reducing insulin dependence. [Extracted from the article]

A study conducted at Zahedan University of Medical Sciences in Iran explored the impact of metformin on serum asprosin levels and FBN1 gene expression in male rats with type 2 diabetes. The research found that metformin treatment significantly reduced serum asprosin levels and downregulated FBN1 gene expression, potentially offering therapeutic benefits beyond improving insulin sensitivity. This study sheds light on the mechanisms by which metformin may benefit individuals with type 2 diabetes. [Extracted from the article]

Researchers from Iran Polymer and Petrochemical Institute have published a study on advanced drug delivery systems for topical insulin in diabetic wound healing. The study highlights the challenges of traditional treatment methods for diabetic foot ulcers and explores the potential of novel therapeutic strategies using insulin. Various delivery platforms such as hydrogels, nanoparticles, liposomes, and microemulsions have been developed to optimize insulin bioavailability and enhance diabetic wound management. The research emphasizes the promise of advanced topical insulin delivery systems in improving patient outcomes and managing diabetic wounds effectively. [Extracted from the article]

Researchers from Federal University Mato Grosso conducted a systematic review on the anti-tumor effect of metformin in cancer patients. The study found that metformin, a drug commonly used to treat type 2 diabetes, showed potential antitumor effects by inhibiting cell growth and proliferation. The research concluded that metformin could improve overall survival in cancer patients without significant adverse effects, both when used alone and in combination with other antineoplastic drugs. The study was published in Scientific Electronic Archives and can be accessed for further information. [Extracted from the article]

Researchers have submitted a patent application for "Penicillin-G Acylases" to the USPTO, aiming to engineer enzymes capable of acylating insulin. The invention focuses on enhancing the stability and efficiency of penicillin G acylase (PGA) for industrial applications in pharmaceutical production. By providing engineered PGA enzymes and polynucleotides, the inventors aim to improve the synthesis of acylated insulin and other pharmaceutical compounds. This patent application highlights advancements in enzyme engineering and biotechnological innovations in the pharmaceutical industry. [Extracted from the article]

A recent study conducted at the University of Nebraska Medical Center in Omaha, Nebraska, focused on evaluating the safety and efficacy of a nonanthracycline, nonplatinum adjuvant treatment regimen for patients with early stage HER2+ breast cancer. The study involved 39 patients who received treatment with dose-dense Paclitaxel, cyclophosphamide, and Trastuzumab, showing high rates of relapse-free survival. The results indicated that the treatment regimen demonstrated overall safety and efficacy, highlighting the potential for improved outcomes in patients with HER2+ breast cancer. [Extracted from the article]

The article discusses a clinical trial, NCT06740838, focusing on improving screening for primary aldosteronism in patients on chronic blood pressure-lowering medications by using 1 mg of dexamethasone before hormonal examinations. Primary aldosteronism is a condition where excessive aldosterone is released, leading to hypertension requiring specific therapy. The study aims to determine if overnight dexamethasone intake can enhance primary aldosteronism screening accuracy in patients on blood pressure-lowering medications. Participants will undergo hormonal examinations and medication modifications to confirm or rule out primary aldosteronism. [Extracted from the article]

A recent study from the Department of Surgery examined the medium- and long-term recurrence rates after radioiodine therapy for differentiated thyroid carcinoma using recombinant human thyrotropin (rhTSH). The research found that there was no significant difference in recurrence rates between the rhTSH group and the thyroid hormone withdrawal (THW) group. While the structural incomplete response rate was slightly higher in the rhTSH group, further randomized controlled trials are needed to determine if rhTSH increases the risk of incomplete response. The study suggests that rhTSH is comparable to THW in achieving successful ablation of residual disease and maintaining low recurrence rates. [Extracted from the article]

A recent patent application discusses a vaginal drug delivery device that can administer various compounds through the vagina, particularly useful for drugs with low oral bioavailability or unwanted gastrointestinal side effects. The device can release compounds based on physiological data gathered from the user, offering controlled release patterns such as continuous, pulsatile, or on-demand release. This innovative approach is suitable for a range of therapeutic classes, including psychiatric, neurological, analgesic, hormonal, cardiovascular, and anticholinergic drugs, providing localized effects with lower doses. [Extracted from the article]

Researchers at the Department of Internal Medicine have published a study on hyperglycemia caused by an overdose of amlodipine, a calcium channel blocker. The study describes a 74-year-old man who experienced toxicity from consuming 88 tablets of amlodipine, leading to hyperglycemia and requiring high-dose insulin therapy. The research concludes that high-dose insulin euglycemic therapy was effective in treating amlodipine overdose and recommends considering this approach in similar cases. The study provides valuable insights into the management of hyperglycemia resulting from calcium channel blocker toxicity. [Extracted from the article]

A patent application titled "Cardiosafe Antidiabetic Therapy" has been submitted by inventor Odd-Erik Johansen, focusing on the cardiovascular safety of linagliptin compared to glimepiride in patients with type 2 diabetes at elevated cardiovascular risk. The application highlights the need for long-term investigations on the safety profile of DPP-4 inhibitors in patients with diabetes and renal impairment. The study aims to assess the impact on cardiovascular morbidity and mortality of linagliptin treatment in comparison to glimepiride, emphasizing the importance of cardiovascular and renal outcomes in diabetes management. [Extracted from the article]

A recent study conducted at Zhongnan Hospital of Wuhan University focused on the role of ITGA5 in autophagy, migration, and invasion of acute myeloid leukemia (AML) cells. The research found that ITGA5 is highly expressed in AML cells and that inhibiting ITGA5 can enhance the effectiveness of chemotherapy drugs like cytarabine and doxorubicin, while also inhibiting the migration and invasion of AML cells. The study suggests that ITGA5 could be a potential target for clinical treatment of AML. [Extracted from the article]

Researchers from Father Muller Medical College in India conducted a prospective cohort study to compare the effectiveness of metformin and insulin in managing gestational diabetes mellitus (GDM) and its impact on maternal and newborn outcomes. The study included 369 pregnant women, with 91.6% on metformin and 8.40% on insulin. Results showed that the metformin group had better glycaemic control, while the insulin group had higher rates of large for gestational age (LGA) babies and infants requiring phototherapy. The research concluded that metformin was more effective in controlling blood sugar levels and had better outcomes for both mothers and newborns. [Extracted from the article]

A clinical trial, NCT06720350, is investigating the efficacy of combining romosozumab with denosumab in postmenopausal osteoporosis patients with a high risk of fragility fractures. The trial aims to determine if adding romosozumab to ongoing denosumab treatment is effective in preventing fractures, and if switching to romosozumab after denosumab treatment has complications. Postmenopausal women with osteoporosis will receive different treatment regimens and undergo regular clinic visits, blood tests, and bone mineral density examinations. The study is not yet recruiting participants and is expected to be completed by December 15, 2026. [Extracted from the article]

A recent study conducted at Hacettepe University Faculty of Medicine in Ankara, Turkey, focused on hyperglycemia in children undergoing treatment for acute lymphoblastic leukemia (ALL). The research found that patient-related factors, such as advanced age, female gender, and central nervous system involvement, were significant predictors for the development of diabetes during the remission period. The study highlighted the importance of monitoring blood glucose levels in children with ALL, especially after relapse, due to the high rate of diabetes observed. The findings suggest that individual characteristics may play a more crucial role in diabetes development than specific drug doses used in treatment protocols. [Extracted from the article]

Researchers at Rutgers University studied the effects of the anticoagulant apixaban on blood clot structure and fibrinolysis. Apixaban inhibits factor Xa, preventing the formation of blood clots by impeding the conversion of prothrombin into thrombin. The study found that apixaban modulates clot structure and lysis differently depending on the clotting activator used, providing insights into potential therapeutic strategies involving apixaban in fibrinolytic pathways. The research was supported by various organizations including the National Institutes of Health. [Extracted from the article]

Researchers at the U.S. Food and Drug Administration have developed a method to quantify antimicrobial preservatives in biopharmaceutical parenteral formulations. The method was validated and applied to three marketed teriparatide drug products, showing comparable preservative concentrations with labeled claims. This research aims to evaluate drug quality and support the assessment of biopharmaceutical peptide drug products. The study was peer-reviewed and provides valuable insights into the development and validation of a headspace GC-MS method for quantifying antimicrobial preservatives in biopharmaceutical peptide formulations. [Extracted from the article]

A new study conducted by a researcher at Peking University Third Hospital in Beijing, China, explores the relationship between genetic variation in targets of antidiabetic drugs and the risk of amyotrophic lateral sclerosis (ALS). The study found that genetic variation in SGLT2 inhibition targets was associated with a lower risk of ALS, while mitochondrial complex I, a target of metformin, was associated with a higher risk of ALS. The research suggests that the complex interaction between hypoglycemic, antioxidation, and anti-inflammatory effects of antidiabetic drugs may influence ALS risk and could guide future therapeutic approaches. [Extracted from the article]

A recent study conducted at Universitas Negeri Surabaya in Indonesia explored the role of insulin-like growth factor (IGF-1) signaling during physical exercise. The research, which involved a systematic review of reputable international journals, found that exercise can increase IGF-1 levels, a hormone that promotes growth. The study highlights the potential of physical exercise as a therapeutic tool to improve public health. For more information, the full article can be accessed for free at https://doi.org/10.47723/frgdrz94. [Extracted from the article]

Researchers at Mutah University conducted a retrospective cohort study on gestational diabetes management in South Jordan, comparing metformin alone to metformin-insulin therapy. The study aimed to assess the cost-benefit ratio of a dedicated GDM clinic, identify risk factors, analyze treatment regimens, and evaluate pregnancy outcomes. Results showed no significant outcome differences between the two treatment groups, but the metformin-insulin therapy group had higher NICU admission rates. The study suggests that a centralized approach to GDM management could lead to improved care and research development in the community. [Extracted from the article]

A new study from Naval Medical University in Shanghai, China, explores the use of fluorous-tagged bortezomib supramolecular nanomedicine for cancer therapy. The research focuses on optimizing lipidation strategies to enhance the therapeutic effect and biocompatibility of anticancer peptide drugs. By integrating fluorination chemistry and supramolecular engineering, the study introduces a novel approach to improving the serum stability of nanomedicine for efficient in vivo utilization in killing cancer cells. The findings suggest promising advancements in cancer treatment through innovative nanomedicine techniques. [Extracted from the article]

A study conducted by researchers at Dokuz Eylul University Faculty of Medicine in Izmir, Turkey, focused on the long-term efficiency of twice-daily exenatide in patients with type 2 diabetes. The study included 287 patients and found that exenatide therapy led to continued improvements in glycemic control and progressive weight loss over a period of 3 years. The research also noted a decrease in insulin dosage for patients treated with insulin. This study provides valuable insights into the real-life effectiveness of exenatide in managing type 2 diabetes. [Extracted from the article]

Researchers at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, conducted a study to evaluate the efficacy and safety of Goserelin acetate in treating uterine fibroids. The study found that Goserelin acetate effectively reduced the volume of uterine fibroids and uterus, lowered estrogen levels, and improved anemia symptoms in premenopausal Chinese women. The treatment was well-tolerated and improved the quality of life for patients. The research was supported by various funding sources and published in Gynecological Endocrinology. [Extracted from the article]

A recent study conducted at the University of Texas Medical Branch explored the association between glucagon-like peptide-1 (GLP-1) agonist use and rates of pseudarthrosis after single-level lumbar fusion surgery. The study, which included 37,147 patients, found that individuals who took GLP-1 agonists had lower odds of developing pseudarthrosis at 6 months, 1 year, and 2 years post-surgery. The researchers concluded that GLP-1 agonists may have a therapeutic benefit in improving spinal fusion outcomes, suggesting the need for further prospective studies to confirm these results and investigate underlying mechanisms. [Extracted from the article]

Recent research from the Second Affiliated Hospital of Guangzhou Medical University focuses on rhabdomyosarcomas, a type of cancer with high metastasis and recurrence rates. The study highlights the potential of inducing pyroptosis in tumor cells as an effective antitumor therapy strategy. Researchers found that GEFT inhibits the pyroptosis pathways in rhabdomyosarcomas, promoting tumor progression and drug resistance. The study suggests that nigericin and dactinomycin can improve therapeutic outcomes by activating the pyroptosis pathway in rhabdomyosarcomas. [Extracted from the article]

Researchers from the Catholic University of Korea have developed a novel method of synthesizing gold nanoparticles using bromelain as a reducing and capping agent, which were then conjugated with methotrexate for targeted therapy in osteosarcoma cells. The study found that these nanoparticles significantly increased the cytotoxic impact on osteosarcoma cells while showing minimal toxicity towards noncancerous cells. This research suggests that these gold nanoparticles can be a potential drug delivery method for osteosarcoma treatment, improving effectiveness and reducing adverse effects. [Extracted from the article]

A patent application by inventors Duckson and Schneider, assigned to DJ Medical LLC, details a self-administered injection device and method for injecting solutions. The device includes an actuation mechanism for inserting the injection needle and a safety mechanism to prevent injection without release. The method involves positioning an injection patch, engaging a cartridge with the device, aligning with a location indicator, and injecting the solution. This innovation aims to provide patients with a means to self-administer injections, particularly for substances like botulinum toxin used for medical and cosmetic purposes. [Extracted from the article]

Researchers at Linkoping University in Sweden have discovered a novel mechanism of action for the anticoagulant drug dabigatran, which is widely used for treating atrial fibrillation and venous thromboembolism. The study found that dabigatran not only blocks the active site of thrombin but also inhibits its binding to platelets, a crucial step in hemostasis. This finding, confirmed through flow cytometry and biomolecular binding studies, may have significant implications beyond cardiovascular health. The research was supported by Hjart-lungfonden and the Swedish Research Council and was published in Thrombosis and Haemostasis. [Extracted from the article]

A recent study published by researchers at Yale University School of Medicine discusses a case of acquired lipodystrophy in a 65-year-old female with melanoma following treatment with pembrolizumab. The patient experienced weight loss, lipoatrophy, and other symptoms of lipodystrophy, leading to the discontinuation of pembrolizumab and initiation of steroid therapy. This case highlights the importance of clinician awareness of potential rare complications associated with pembrolizumab treatment for advanced melanoma. The study was published in Current Problems in Cancer: Case Reports and is available for further reading. [Extracted from the article]

A recent study conducted at West China Second University Hospital in Chengdu, China, focused on enhancing the efficacy of peptide vaccines for Human Papillomavirus (HPV)-related cancers. The research highlighted the importance of developing therapeutic vaccines to protect individuals infected with HPV and prevent tumor progression. The study emphasized the need for improved immunogenicity of HPV peptide-based vaccines through combination therapies and enhanced delivery strategies. Further research is required to validate these approaches as standard treatments for HPV therapeutic peptide-based vaccines. [Extracted from the article]

A recent study conducted at Northern Technical University compared the effects of metformin and insulin on biochemical variables in diabetic patients. The research highlighted the importance of managing type 2 diabetes through careful monitoring of blood glucose levels and lifestyle modifications. The study found that while both metformin and insulin treatments had varying effects on lipid profiles and liver and kidney functions, further research is needed to fully understand their impact on diabetic patients. For more information, readers can access the full article in Endocrine and Metabolic Science. [Extracted from the article]

A recent study conducted by researchers at the University of Castilla-La Mancha in Spain explored the effects of a 12-week concurrent training program on metabolic markers and cardiorespiratory fitness in individuals with insulin resistance (IR), with and without metformin treatment. The study included overweight/obese participants divided into three groups: exercise group, exercise-metformin group, and metformin-only control group. Results showed that both exercise groups experienced improvements in metabolic markers, insulin sensitivity, and fat oxidation, while the metformin-only group saw a decrease in cardiorespiratory fitness. The findings suggest that the training program, with or without metformin, was effective in improving metabolic markers in individuals with IR. [Extracted from the article]

Researchers at the University of Miami Miller School of Medicine have highlighted the significance of alpha cell function in the pathophysiology of Type 1 Diabetes (T1D). The autoimmune destruction of beta cells in T1D can lead to dysregulation of alpha cell function, resulting in elevated glucagon levels and impaired glucose homeostasis. Understanding the role of alpha cells in T1D is crucial for developing new therapeutic strategies to improve glycemic control and reduce the risk of hypoglycemic events in individuals with T1D. The research suggests potential approaches such as targeting alpha cells, utilizing glucagon receptor antagonists, enhancing GABA signaling, and employing GLP-1 receptor agonists to address alpha cell dysfunction in T1D. [Extracted from the article]

Researchers at the University of Health Sciences conducted a study on the efficacy of levothyroxine monotherapy in achieving clinical euthyroidism and its impact on weight loss in women with hypothyroidism and obesity. The retrospective study included 138 subjects with obesity, 69 women with hypothyroidism on levothyroxine, and 69 age- and BMI-matched women without thyroid disease. The results suggest that achieving euthyroid status through levothyroxine monotherapy in hypothyroid women leads to weight loss responses comparable to those in women with normal thyroid, supporting current hypothyroidism treatment strategies. [Extracted from the article]

Researchers from the Russian Academy of Sciences conducted a study on the effects of insulin-like growth factor-1 (IGF-1) on oocyte and embryo development in mice under chronic psychosocial stress. The study found that chronic stress negatively impacted oocyte development and mitochondrial function, but IGF-1 treatment improved oocyte and embryo quality. This research suggests a potential therapeutic role for IGF-1 in enhancing reproductive outcomes under stress conditions. The study was supported by the Russian Science Foundation and has been peer-reviewed. [Extracted from the article]

A recent study conducted at Beckman Research Institute in Duarte, California, focused on pancreatic cancer and the role of desmoplasia in treatment resistance. Researchers engineered a tumor-colonizing E. coli agent expressing collagenase and hyaluronidase to reduce desmoplasia and enhance drug delivery in pancreatic tumors. The study found that the combination of these enzymes led to reduced intratumoral collagen and hyaluronan, ultimately enhancing the efficacy of chemotherapy in pancreatic cancer models. This research underscores the importance of combination treatments targeting desmoplastic components in pancreatic cancer therapy. [Extracted from the article]

A clinical trial, NCT06688799, is being conducted at Beijing GoBroad Hospital to evaluate the safety and efficacy of CD19 CAR T cells in treating Refractory Autoimmune Diseases. The trial aims to determine the optimal biological dose and assess the overall response rate in patients with autoimmune diseases. The study involves patients with various autoimmune conditions, including lupus, Sjogren's syndrome, and systemic sclerosis, and is expected to enroll 18 subjects. The primary outcomes include dose-limiting toxicity and overall response rate, with a completion date set for September 30, 2025. [Extracted from the article]

A recent study conducted by researchers at the Dana-Farber Cancer Institute in Boston, Massachusetts, focused on treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BCBMs). The study examined the efficacy of neratinib plus T-DM1 in patients with HER2-positive BCBM, showing promising results in terms of intracranial activity and overall survival. The research concluded that neratinib-based combinations could be beneficial for patients with HER2-positive BCBM, even those who have been heavily pretreated. This study was funded by various organizations, including Puma Biotechnology, Inc., and has been peer-reviewed. [Extracted from the article]

A recent study conducted at the University Medical Center Ljubljana in Slovenia explored the effects of an empagliflozin/metformin combination on overweight individuals with type 1 diabetes and high cardiovascular risk. The study, which included 40 participants, found that the combination therapy improved glycemic control, reduced weight, and insulin requirements, while also producing other beneficial metabolic effects. The research concluded that the empagliflozin/metformin combination could be a promising treatment option for individuals with type 1 diabetes at increased cardiovascular risk. [Extracted from the article]

A recent study conducted at the University of Washington examined the impact of insulin sensitivity and beta-cell function on glycemic outcomes in response to dual therapy for diabetes. The study found that higher insulin sensitivity and C-peptide responses were associated with better initial treatment responses and lower risk of glycemic failure. These associations varied depending on the type of treatment received, with sitagliptin showing greater impact on initial HbA(1c) reduction compared to other therapies. The research, which has been peer-reviewed, provides valuable insights into the effectiveness of different antidiabetic agents in managing diabetes. [Extracted from the article]

Researchers at the Second Affiliated Hospital in Shandong, China, conducted a study on the efficacy and safety of Inetetamab combined with S-1 and oxaliplatin as a first-line treatment for HER2-positive advanced gastric cancer. The study involved 38 patients who were randomly divided into two groups, one receiving Inetetamab and the other receiving trastuzumab. Results showed that Inetetamab demonstrated superior progression-free survival compared to trastuzumab, with comparable overall survival rates and adverse event profiles. This research has been peer-reviewed and provides valuable insights into potential treatment options for HER2-positive gastric cancer patients. [Extracted from the article]

Researchers at Shanghai Jiao Tong University School of Medicine have conducted a study on kidney cancer, specifically focusing on the mechanisms and treatment of sunitinib resistance in renal cell carcinoma (RCC). The study highlights the increasing morbidity and mortality rates of RCC, emphasizing the importance of targeted therapies like sunitinib in controlling tumor progression. However, the research also addresses the challenge of sunitinib resistance in RCC patients, aiming to provide insights for developing more effective treatment strategies. This study offers valuable information for individuals interested in advancements in RCC treatment and overcoming drug resistance. [Extracted from the article]

A recent study conducted at Jawaharlal Nehru Medical College in India focused on metabolic-associated steatotic liver disease (MASLD), which is a common cause of chronic liver disease globally. The research highlighted the potential benefits of using antiplatelet drugs, specifically aspirin, in managing MASLD by reducing hepatic inflammation, oxidative stress, and insulin resistance, potentially preventing hepatic fibrosis progression. The study emphasized lifestyle modifications and treating coexisting conditions like obesity, hyperlipidemia, insulin resistance, and type 2 diabetes as part of the current management strategies for MASLD. For more information, the full article can be accessed through the European Journal of Gastroenterology & Hepatology. [Extracted from the article]

Researchers at Ain Shams University conducted a study on the potential benefits of combining Bacillus Calmette-Guerin (BCG) vaccine with liraglutide and probiotics in treating Type 1 diabetes in rats. The study found that this combination showed promise in suppressing pyroptosis of pancreatic islets and improving glucose homeostasis parameters. The research suggests that this combined therapy could be a promising approach in managing Type 1 diabetes mellitus by targeting the pancreatic TXNIP/NLRP3 signaling pathway. [Extracted from the article]

Researchers at Bogomolets National Medical University in Kyiv, Ukraine, have published a study on the pathogenetic basis of treating endothelial dysfunction with metformin in patients with diabetes. The study highlights the impact of hyperglycemia on cardiovascular health and the beneficial effects of metformin in reducing insulin resistance and improving vascular health. The research suggests that metformin could be a safe and effective treatment for hyperglycemia and cardiovascular diseases, particularly in addressing endothelial dysfunction and atherosclerosis. For more information, the full article can be accessed in the Mižnarodnij Endokrinologicnij Žurnal. [Extracted from the article]

Researchers from the Russian Academy of Sciences conducted a study on the efficacy of combining Metformin and intranasal insulin to treat rats with cafeteria diet-induced obesity. The study found that this combination normalized body weight, restored glucose homeostasis, and improved insulin sensitivity in the rats. The research concluded that a combined course of Metformin and low-dose intranasal insulin showed promise in correcting metabolic and hormonal indices in diet-induced obesity without negative effects on the thyroid axis. [Extracted from the article]